Table 2.
Hazard ratios of mortality according to baseline variables in HIV-infected patients starting ART in Tanzania
| Unadjusted | Adjusteda | |||
| Baseline variables | HR (95% CI) | P | HR (95% CI) | P |
| Gender (male vs. female) | 1.73 (1.15–2.61) | 0.009 | 1.60 (1.00–2.57) | 0.053 |
| WHO stage (IV vs. I–III) | 2.71 (1.64–4.49) | <0.001 | 1.46 (0.81–2.65) | 0.210 |
| ART start year (vs. 2003–04) | ||||
| 2005 | 0.55 (0.35–0.87) | 0.010 | 0.64 (0.38–1.08) | 0.091 |
| 2006 | 0.30 (0.17–0.56) | <0.001 | 0.40 (0.19–0.83) | 0.014 |
| BMI (vs. ≥ 18.5 kg/m2) | ||||
| <16 | 4.17 (2.29–7.60) | <0.001 | 2.12 (1.06–4.24) | 0.034 |
| 16–18.4 | 1.60 (0.82–3.10) | 0.168 | 1.27 (0.62–2.61) | 0.516 |
| Hemoglobin (vs. ≥ 12 g/dL for women and ≥ 13 for men) | ||||
| <8 | 22.7 (5.40–95.7) | <0.001 | 9.20 (2.05–41.3) | 0.004 |
| 8–9.9 | 13.5 (3.28–55.9) | <0.001 | 7.50 (1.77–31.9) | 0.006 |
| 10–11.9 (10–12.9 for men) | 6.21 (1.46–26.5) | 0.014 | 4.03 (0.93–17.5) | 0.063 |
| TLC (vs. ≥ 1.2 × 109/L) | ||||
| <0.6 | 3.58 (2.05–6.24) | <0.001 | 1.72 (0.87–3.39) | 0.117 |
| 0.6–1.1 | 1.10 (0.69–1.74) | 0.699 | 0.79 (0.48–1.32) | 0.371 |
| Platelet count (<150 vs. ≥ 150 × 109/L) | 2.23 (1.40–3.57) | 0.001 | 2.30 (1.33–3.99) | 0.003 |
aCox proportional hazards model adjusted for all variables listed in the table.
HR, hazard ratio; CI, confidence interval; ART, antiretroviral therapy; WHO, World Health Organization; BMI, body mass index; TLC, total lymphocyte count.